ArticleHead and neck pathology2026
The SALV-Dataset Registry: An Expertly Curated Digital Clinicopathological Dataset for Salivary Gland Tumor Research and AI-Assisted Diagnostic Tools.
Article in Head and neck pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Salivary gland tumors are rare and morphologically diverse, posing both diagnostic and scientific challenges. This study presents the first phase of the SALV-Dataset Registry; a nationwide, expertly curated, and fully digitized clinicopathological resource, designed to support research and develop artificial intelligence (AI) tools assisting in salivary gland tumor pathology diagnostics.
methodsSalivary gland tumor resections diagnosed at the Leiden University Medical Center (1999-2024) were collected through the Dutch national network and registry for histo- and cytopathology (PALGA). In total, 685 cases were included. Hematoxylin- and eosin-stained slides were digitized and independently reviewed by three teams of head and neck pathologists, in line with the 2023 WHO Classification of Head and Neck Tumours. Discordant and ambiguous cases were resolved in consensus meetings, with access to immunohistochemistry, molecular analysis, and clinical data. Interobserver agreement among the three teams was quantified (Fleiss' kappa), and agreement between the original and consensus diagnosis was determined (Cohen's kappa).
resultsOf the 685 tumors, 75% were benign, 24% malignant, and 1% of uncertain malignant potential. The parotid gland was most frequently involved (86%), and the highest rate of malignancy was observed in the sublingual gland (100%). Rare entities were represented, although numbers remained limited. Interobserver agreement was substantial (κ of 0.64; 95% 0.60-0.67). Agreement between the original and consensus diagnosis was excellent (Cohen's κ of 0.89; 95% CI 0.86-0.92). Forty-three cases (6%) were reclassified following revision, with a change in diagnostic category in 11 cases (2%).
conclusionThis study demonstrates the feasibility of large-scale, expert digital revision of salivary gland tumors, and establishes a robust foundation for future clinicopathological and AI-based research. With national expansion ongoing, the SALV-Dataset Registry will provide a comprehensive resource for AI training, validation, and clinically oriented modeling in salivary gland tumor diagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.